Free Trial

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Sees Significant Decrease in Short Interest

Curaleaf logo with Medical background
Remove Ads

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 6,337,300 shares, a drop of 9.0% from the January 15th total of 6,962,300 shares. Based on an average daily trading volume, of 1,348,400 shares, the short-interest ratio is presently 4.7 days.

Curaleaf Stock Down 0.7 %

Shares of CURLF traded down $0.01 on Friday, hitting $1.41. 529,682 shares of the stock traded hands, compared to its average volume of 767,267. The company has a market capitalization of $931.47 million, a PE ratio of -4.86 and a beta of 0.60. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. The business has a 50 day simple moving average of $1.47 and a 200 day simple moving average of $2.29. Curaleaf has a one year low of $0.88 and a one year high of $6.40.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CURLF. Roth Capital raised shares of Curaleaf to a "strong-buy" rating in a research note on Sunday, November 10th. Cormark downgraded shares of Curaleaf from a "moderate buy" rating to a "hold" rating in a research note on Thursday, November 7th.

View Our Latest Report on CURLF

Curaleaf Company Profile

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Featured Stories

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

5 Stocks to BUY NOW in February 2025

5 Stocks to BUY NOW in February 2025

With the market holding strong, inflation concerns persisting, and major earnings reports ahead, these stock picks could be game-changers for your portfolio!

Recent Videos

Best ETFs for Spring 2025: Strong and Steady Investing
Is There Still Money in AI? How to Invest in the Next Big Wave
AMD at Rock Bottom? Analysts Predict a MAJOR Rebound!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads